Are Wall Street Analysts Predicting STERIS Stock Will Climb or Sink?
STERIS plc (STE) has lagged the market, falling 11.2% over the past year versus a 27.9% S&P 500 gain, and is down 14.6% in 2026 YTD. After Q4 results on May 11 (revenue $1.6B, +7.3% YoY; adjusted EPS $2.83, +3.3%), analysts expect FY2027 EPS of $11.18 (+9.9%). Consensus is “Moderate Buy” (5 “Strong Buy,” 3 “Hold”); KeyBanc cut its target to $269.
How this was made
The 30-second read
Why it matters
The trading signal is driven by analyst positioning after earnings: consensus remains supportive, but the downgrade in rating mix versus three months ago and STE’s underperformance increase the probability of choppy price action around future guidance/EPS prints.
Market read
For traders, the actionable takeaway is the gap between current price and Street targets (mid/high) alongside a still-positive but less bullish rating mix.
What to watch
Mixed earnings surprise history (3/4 quarters met) implies volatility around consensus; also, the article notes rating optimism has cooled versus three months ago, which can cap upside even with price targets.
Background
The piece summarizes STE’s recent performance versus broader benchmarks, its May 11 Q4 results, and current Wall Street consensus (ratings and price targets).
Ticker impact
STE shares fell after its May 11 Q4 results, but analysts still rate it a Moderate Buy with a KeyBanc Overweight and raised upside via a $269 target.
Bias modestly positive, with upside skew if upcoming results validate the ~9.9% FY2027 EPS growth outlook; otherwise downside risk given mixed surprise history.
The article provides analyst rating/target dispersion plus the latest Q4 beat/miss context, but no new fundamental catalyst beyond consensus framing.
Market effects
Medical devices/infection prevention names may see mild read-across from STE’s EPS trajectory and analyst target revisions, but the article is primarily company-specific.
Limited—no regional regulatory or macro catalyst is cited; focus is on US-listed analyst expectations.
Low—no international deal/regulatory development is mentioned; relevance is largely confined to investor sentiment around STE.
Counterpoint
Despite a Moderate Buy, STE’s recent YTD and 1Y underperformance versus the S&P 500 and the iShares Medical Devices ETF suggests the market may be discounting slower momentum or execution risk.
Key entities
- companySTERIS plc
Infection prevention products/services provider; article covers May 11 Q4 results and current analyst ratings/targets for FY2027 EPS.
- analyst_firmKeyBanc Capital Markets
Maintained an Overweight rating on STE while lowering its price target to $269.
